Alkermes plc. market cap ALKS
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $7.5B
- Highest close in our data
- $11.9B
- Dec 2015
Alkermes plc. is worth $7.5B at the close on Nov 2, 2026, at $44.89 a share.
That is up 39% over the last year and up 54% over five years.
Its highest close in our data was $11.9B in Dec 2015.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $7.5B | $4.6B | $9.2B | +60% |
| 2025 | $4.7B | $4.3B | $5.8B | −2% |
| 2024 | $4.8B | $4B | $5.4B | +3% |
| 2023 | $4.6B | $4B | $5.5B | +8% |
| 2022 | $4.3B | $3.6B | $5.2B | +14% |
| 2021 | $3.8B | $3B | $5.2B | +18% |
| 2020 | $3.2B | $2.1B | $3.5B | −1% |
| 2019 | $3.2B | $2.8B | $5.8B | −27% |
| 2018 | $4.4B | $4.4B | $10.5B | −47% |
| 2017 | $8.4B | $7.4B | $9.4B | −0% |
| 2016 | $8.4B | $4.6B | $10.7B | −29% |
| 2015 | $11.9B | $8.5B | $11.9B | +41% |
| 2014 | $8.4B | $5.5B | $8.6B | +51% |
| 2013 | $5.6B | $2.7B | $5.6B | +128% |
| 2012 | $2.4B | $2B | $2.7B | +9% |
| 2011 | $2.2B | $1.8B | $2.3B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Alkermes plc.'s size, closest first, today.
| Company | Market cap |
|---|---|
| ALKSAlkermes plc. | $7.5B |
| KNSAKiniksa Pharmaceuticals International | $7.1B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| CORTCorcept Therapeutics | $8.7B |
| PTGXProtagonist Therapeutics | $9B |
| TGTXTG Therapeutics | $9.2B |
| LGNDLigand Pharmaceuticals | $6.1B |
| BMRNBiomarin Pharmaceutical | $11.1B |
| INDVIndivior Pharmaceuticals | $4.3B |
| JAZZJazz Pharmaceuticals | $13.9B |
| ARQTArcutis Biotherapeutics | $3.9B |
| Peer median | $7.9B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Alkermes plc.
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.